Novartis AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
- Introduction
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
A 12 Month Core Study to Assess the Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema and a 24 Month Open-label Extension Study
- Conditions
- Diabetic Macular Edema
- Interventions
- First Posted Date
- 2008-06-02
- Last Posted Date
- 2013-04-01
- Lead Sponsor
- Novartis
- Target Recruit Count
- 345
- Registration Number
- NCT00687804
- Locations
- 🇨🇭
Novartis Investigational Site, Zurich, Switzerland
🇬🇧Novartis Investigative Site, Upton, United Kingdom
Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease
- Conditions
- Cryopyrin-Associated Periodic SyndromesMuckle Wells SyndromeFamilial Cold Autoinflammatory SyndromeNeonatal Onset Multisystem Inflammatory Disease
- Interventions
- First Posted Date
- 2008-05-28
- Last Posted Date
- 2016-11-04
- Lead Sponsor
- Novartis
- Target Recruit Count
- 166
- Registration Number
- NCT00685373
- Locations
- 🇺🇸
Little Rock Allergy and Asthma Clinic, Little Rock, Arkansas, United States
🇺🇸UCSF School of Medicine, San Francisco, California, United States
🇪🇸Novartis Investigative Site, Vigo, Spain
Safety, Tolerability and Efficacy of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
- First Posted Date
- 2008-05-15
- Last Posted Date
- 2011-08-22
- Lead Sponsor
- Novartis
- Target Recruit Count
- 415
- Registration Number
- NCT00677807
- Locations
- 🇹🇷
Novartis Investigative Site, Kartal/Istanbul, Turkey
🇺🇸Novartis Investigative SIte, Fullerton, California, United States
🇹🇷Novartis Investigator Site, Yenisehir/Izmir, Turkey
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effect of PTH134 at Increasing Doses in Healthy Postmenopausal Subjects
- Conditions
- Postmenopausal Osteoporosis
- Interventions
- Drug: PTH134
- First Posted Date
- 2008-05-13
- Last Posted Date
- 2008-12-11
- Lead Sponsor
- Novartis
- Target Recruit Count
- 32
- Registration Number
- NCT00676312
- Locations
- 🇨🇭
Novartis Investigative site, Basel, Switzerland
Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron Overload
- Conditions
- HemoglobinopathiesMyelodysplastic SyndromesOther Inherited or Acquired AnaemiaMPD SyndromeDiamond-Blackfan AnemiaOther Rare AnaemiasTransfusional Iron Overload
- Interventions
- First Posted Date
- 2008-05-07
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 118
- Registration Number
- NCT00673608
- Locations
- 🇦🇺
Novarts Investigative Site, Sydney, Australia
Efficacy and Safety of Verteporfin Added to Ranibizumab in the Treatment of Symptomatic Macular Polypoidal Choroidal Vasculopathy
- Conditions
- Polypoidal Choroidal Vasculopathy
- Interventions
- First Posted Date
- 2008-05-07
- Last Posted Date
- 2011-04-19
- Lead Sponsor
- Novartis
- Target Recruit Count
- 61
- Registration Number
- NCT00674323
- Locations
- 🇹🇭
Novartis Investigative Site, Bangkok, Thailand
An Extension Study of the Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing Multiple Sclerosis
- First Posted Date
- 2008-05-01
- Last Posted Date
- 2013-09-04
- Lead Sponsor
- Novartis
- Target Recruit Count
- 143
- Registration Number
- NCT00670449
- Locations
- 🇯🇵
Novartis Investigative Site, Wakayama, Japan
Study to Determine the Onset of Action of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: Salmeterol/fluticasone (50/500 μg)Drug: Placebo to Salmeterol/fluticasone
- First Posted Date
- 2008-04-30
- Last Posted Date
- 2011-09-12
- Lead Sponsor
- Novartis
- Target Recruit Count
- 89
- Registration Number
- NCT00669617
- Locations
- 🇭🇺
Novartis Investigative site, Deszk, Hungary
🇭🇺Novartis Investigative Site, Nyiregyhaza, Hungary
🇩🇪Novartis Investigator Site, Potsdam, Germany
A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Essential Hypertension
- Conditions
- Essential Hypertension
- Interventions
- First Posted Date
- 2008-04-28
- Last Posted Date
- 2021-06-07
- Lead Sponsor
- Novartis
- Target Recruit Count
- 564
- Registration Number
- NCT00667719
- Locations
- 🇹🇷
Investigative Site, Turkey, Turkey
The Effects of Moderate vs. Aggressive Treatment With Valsartan + Amlodipine on Patients With Hypertension Uncontrolled by Angiotensin-Receptor Blocker (Herein, ARB) Monotherapy
- First Posted Date
- 2008-04-25
- Last Posted Date
- 2016-10-27
- Lead Sponsor
- Novartis
- Target Recruit Count
- 728
- Registration Number
- NCT00666536
- Locations
- 🇺🇸
Egan Healthcare, Metairie, Louisiana, United States